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INTRODUCTION
Uterine leiomyomas affect up to 30% of reproductive-aged women 
and they represent the most common gynecologic neoplasm in 
females.1,2 Diagnosis of classic uterine leiomyomata by radiology is 
not complex given their typical features on imaging and clinical mani-
festations. Ultimately, tissue diagnosis is definitive when leiomyoma 
is suspected on radiological imaging to distinguish it from leiomyo-
sarcoma or other neosplasms. Leiomyomas are hormone-driven and 
most commonly arise from the uterus, but uncharacteristically can 
originate in the vulva, ovaries, bladder, and urethra.3 In addition, on 
rare occasions, they have been discovered in the tissues of bone, deep 
soft tissues, skin, mediastinum, skeletal and cardiac muscle, lymph 
nodes, omentum, mesentery, and retroperitoneum.4 
Metastasis of uterine fibroids are rare events and have been given 
such names as benign metastasizing leiomyoma (BML), intravenous 
leiomyomatosis (IVL), disseminated peritoneal leiomyomatosis 
(DPL), retroperitoneal leiomyomatosis (RPL), and parasitic leiomy-
oma (PL).3 Multiple mysterious pulmonary nodules resulting from 
BML were first described by Marshall and Morris5 and Steiner.6 BML 
can be observed as a mass with histologically benign features, but 
also can demonstrate metastatic potential and present with diffuse 
lung tumors. This rare disease has gone by many titles. However, the 
current term, ‘benign metastizing leiomyoma’, represents a contra-
indication in the nomenclature. Steiner6 recommended the use of 
the term “metastasizing fibroleiomyoma”, as he thought the label of 
“benign” was incorrect. 
Intravenous leiomyomatosis (IVL) is historically more rare than 
BML.7 Even more of an oddity, IVL can extend into the cardiopulmo-
nary system including the right atrium, right ventricle, and pulmonary 
arteries. When this extension of these lesions into the cardiac system 
is present, IVL is termed intracardiac leiomyomatosis (ICLM). In 
1974, ICLM was first reported in English.8 Likely due to technological 
advancements in imaging techniques, ICLM is being reported more 
often. However, definitive diagnosis is determined by postoperative 
pathological evaluation. IVL with cardiac extension is histologically 
benign. Thus, necrosis, mitoses, or cellular irregularities are rare.9 
The tumors described above are typically benign entities, but 
uncommonly transition toward tissues of malignant potential. For 
two women who sought treatment for BML and IVL in our clinic, the 
primary goal was to outline and evaluate their specific genetic, patho-
logical, and clinical features with the intention to elucidate possible 
treatment options.
CASE PRESENTATIONS
Case 1.  A healthy, premenopausal, non-smoking, 30-year-old, 
Vietnamese woman with a negative family history of cancer was 
referred for multiple lung lesions. Two years prior, she underwent 
total hysterectomy for uterine fibroids. At that time, a single uterine 
fibroid was excised. Pathology confirmed a diagnosis of leiomyoma. 
She initially presented with the chief complaints of flu-like symp-
toms and intermittent chest pain. Chest x-rays showed bilateral lung 
lesions. Bilateral breast mammograms showed no evidence of disease. 
Over the following years, the patient underwent an extensive outpa-
tient workup, which included chest computed tomography (CT) scans 
and thoracoscopy, as well as bronchoscopy and bronchial washings, 
which proved to be unremarkable. Lung tissue biopsy was performed 
approximately nine years following the patient’s hysterectomy. Lung 
biopsies revealed benign-appearing smooth muscle nodules. Patholo-
gy showed a low mitotic index. These findings, along with the absence 
of coagulative necrosis and atypia, suggested the diagnosis of BML. 
Over the course of the next two decades, the patient was evaluated 
by multiple specialists. Her lung lesions persisted despite exhaustive 
regiments, including preliminary progesterone therapy. Megestrol, 
tamoxifen, and medroxyprogesterone were added to her therapy regi-
ment. No toxicities from these medications were observed. 
She was referred to M.D. Anderson Cancer Center. Leuprolide and 
letrozole recommendations were made for her uterine leiomyoma 
metastasis of the lungs. No curative therapy was identified. Being that 
it was nine years post-hysterectomy, additional lung lesion tissue was 
acquired. Immunostaining revealed full negativity to c-kit and Her2/
neu, but mixed negative epidermal growth factor receptor (EGFR) 
results with slightly positive staining of material among muscle cells 
and not the muscle cells themselves. More recently, genomic sequenc-
ing by Foundation® testing was performed with patient blood samples. 
An ALK: N1532D variant of unknown significance (VUS) was discov-
ered. The patient was being conservatively managed with observation 
and symptom management. 
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presented to the emergency department with the chief complaint 
of abdominal pain. Ultrasound showed a large mass and follow-up 
CT scans revealed a pelvic mass. Surgical specialists performed a 
total hysterectomy and bilateral oophorectomy. At that time, a well-
circumscribed mass was noted, solely adherent to the uterus and 
infundibulopelvic ligament. Pathology supported a diagnosis of leio-
myoma. Serial sections of well-circumscribed right ovarian portions 
exhibited endometriotic cyst features, spindle cells without cytologic 
atypia, low mitotic activity, and absent malignant features. Spindle 
cell stromal growth predominated with similarities to fibromatosis 
(not otherwise specified). 
Over time, the patient developed lung, cardiac, and intra-abdom-
inal masses. Subsequent exploratory procedures revealed further 
gynecological tissue involvement, as well as retroperitoneal and 
extensive caval thrombus that extended bi-directionally into iliac 
veins and right atrium. At that time, approximately ten years post-
hysterectomy, needle core biopsy of the intra-abdominal mass 
determined Müllerian origins, with benign smooth muscle features 
on histology. Immunostains of the tissue were negative for CD10, 
inhibin, S100, CD34, CD17, pancytokeratin CK7, and RCC. Desmin, 
actin, estrogen receptor, and WT-1 reacted positively, supporting a 
Müllerian origin. Emergent surgical intervention was considered. 
Ultimately, caval thrombus mobilization, inferior vena cava recon-
struction, total tricuspid porcine valve replacement, bipolar epicardial 
ventricular lead device placement (BEV), right radical nephrectomy, 
and removal of several large perirenal and retroperitoneal masses 
(> 5 cm) were performed. Samples from surgery were taken in all 
major areas. All tissue samples showed tumors made of spindle cells 
and absent necrosis and mitotic events. Ki67 testing showed a pro-
liferation rate of less than 1%. Tissues with a vascular background 
were positive for CD34 (i.e., right atrium). Considering the patient’s 
history, presentation, tissue histopathology, and symptom progres-
sions, the etiology of her disease was determined to be most likely due 
to IVL. After the patient’s multiple surgical interventions and stabil-
ity were confirmed, she was discharged and followed as an outpatient. 
Recently, the patient’s tumor tissue specimens were analyzed with 
the genomic sequencing assay Foundation® to determine if the etiol-
ogy of this condition could be due to somatic and/or environmental 
mutations. Testing identified three variants of unknown significance: 
EGFR:V674I, ERBB4:K1002R, and TSC2:L826M.
DISCUSSION
Pathogenesis and Clinical Findings. Uterine leiomyomas are 
the most common gynecological tumor in women of reproductive 
age.1,2 These tumors typically are benign entities but uncommonly 
can make transitions toward tissues of malignant potential. Rare 
growth patterns of uterine leiomyomata have been observed, which 
include BML, IVL, DPL, RPL, and PL.3 The pathogenesis of these 
rare growth patterns is unclear. Furthermore, it remains uncertain 
which atypical growth pattern predominates over the others, due to 
all of their individual rarity. Based on the literature, BML, DPL and 
RPL has been observed to be more indolent.3, 10-13 
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In contrast, IVL has more aggressive characteristics.9 The most 
common findings in patients diagnosed with BML are single or mul-
tiple subcentimetric lung nodules with or without a concomitant 
diagnosis of uterine fibroids, DPL, or IVL. The pathogenesis of BML 
is remains unclear. However, it has been postulated BML spreads 
hematogenously, originates from independent multiple foci, and/or is 
hormone-driven.3, 10-13 Other atypical growth patterns that have been 
found to be hormone-driven include DPL, RPL, and PL. IVL has the 
unique feature of being incompletely hormone-driven. Clinical and 
pathological findings characteristic of IVL consist of in intraluminal 
growth in uterine and/or systemic veins, cord-like vessel lesions, and 
intracardiac extension, and tricuspid valve insufficiency.3, 10-13
The pathogenesis of these atypical growth patterns of uterine 
leiomyoma is unclear and controversial. These growth patterns are 
the result of clonal expansion of smooth muscle cells of the uterus, 
without significant cellular atypia or high mitotic index.14, 15 In con-
trast, leiomyosarcomas frequently exhibit the higher turnover rates 
and atypia. In addition, they rarely are seen with frequency rates of 
0.1 to 6%.16 Primary lesions from these atypical growth patterns could 
be low-grade, slow growing leiomyosarcomas with inherently intact 
metastatic potential.17 Also, erroneous sampling falsely could support 
the diagnosis of benignity.18 However, recent cytogenetic studies have 
refuted this claim by showing that in contrast to leiomyosarcomas, 
these lesions have identical X-chromosome inactivation and a bal-
anced karyotype.19,20
Metastasis of uterine fibroids most commonly appear several 
years after the diagnosis and removal of uterine leiomyomata by 
hysterectomy. Thus, prior gynecological surgery such as hysterec-
tomy or myomectomy is a risk factor for developing any of these rare 
growth patterns that originate from benign uterine fibroids. In our 
two cases, the interval between uterine fibroid diagnosis, hysterecto-
my, and metastasis was two and zero years, respectively. Based on the 
review of literature, IVL appears to be less common phenomenon. 
An earlier report reviewing ten cases of BML observed an interval 
range of four to 23 years (mean 14.9 years) from the time of therapeu-
tic hysterectomy to BML diagnosis.17 The data remained consistent 
with preceding case review work that described the interval between 
hysterectomy to BML diagnosis that ranged from three to 20 years 
(mean 10 years).6
Genomic Sequencing. Genomic sequencing by Foundation® 
testing of blood and tissue samples from the patients in Cases 1 and 2 
identified no genomic mutations in any currently established cancer-
related gene. However, one variant of unknown significance (VUS) 
was detected in Case 1, ALK:N1532D, and three were detected in 
Case 2, EGFR:V674I, ERBB4:K1002R, and TSC2:L826M. In all 
samples from case patients, microsatellite status was determined to 
be stable and the overall tumor mutation burden was low (0.80 muta-
tions/Mb).
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These variants are termed as such because their alterations may not 
have been characterized adequately in the scientific literature at the 
time genomic sequencing was performed and/or the genomic context 
of these variants remains unclear. Thus, their clinical significance can 
neither be supported nor denied. Heightened VUS awareness poses 
a challenge to physicians not only for determining their relevancy, but 
for effectively communicating their importance to patients. Recent 
efforts have been made by National Center for Biotechnology Infor-
mation (NCBI) to track and catalogue newly discovered variants 
with clinically relevant phenotypes.21 We postulate that these variants 
could be targeted as treatment options in the future when patients 
have failed all other previous therapies. 
Treatment. The benign versus malignant potential of BML and 
IVL remains unclear. Currently, there are no definitive guidelines 
regarding management due to their rare nature. BML is not only 
reliant on estrogen and progesterone, but also the majority of BML 
tumors are ER positive.22 GnRH analogs have been successful in 
treating BML.23,24 Progesterone antagonists have been discussed as 
possible adjuvant therapy for BML patients, but certain investigators 
advise against the use of these agents, at least not alone, because of 
their ability to up-regulate estrogen receptors.25 Rivera et al.26 believed 
anastrozole and raloxifene combination therapy could be as effec-
tive as the more traditionally used GnRH agonists and progesterone, 
even in postmenopausal patients with BML. Based on BML’s close 
relationship to uterine leiomyomas, some investigators are optimistic 
raloxifene could be a suitable treatment option for BML. The litera-
ture is unclear on the effectiveness of tamoxifen on BML lesions.23,26
IVL with cardiac extension, such as with the patient in Case 2, has 
been described in the literature and termed intracardiac leiomyo-
matosis (ICLM).8 ICLM is histologically benign. However, ICLM is 
suggested to be clinically aggressive due to the risk of sudden death 
caused by total outflow tract obstruction. Complete removal is the 
recommended treatment. Neoadjuvant and adjuvant anti-estrogen 
regiments or radiation therapy alone have not been shown to be a 
curative solution. This is due to the historical nature of IVL tumors to 
be incompletely hormone-driven. Finally, incomplete removal is not 
recommended due to previous studies reporting a near 30% recur-
rence rate if complete removal is not performed.9
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